Everyday Health on MSN
C3G/IC-MPGN progression: Can new C3 inhibitors stop the path to dialysis?
For years, patients with C3G and IC-MPGN had few options to stop the progression toward kidney failure. Now a new class of ...
The FDA granted accelerated approval to iptacopan (Fabhalta) for primary immunoglobulin A (IgA) nephropathy, a rare progressive disease where the immune system attacks the kidneys, Novartis announced ...
Hosted on MSN
6 types of treatment for complement 3 glomerulopathy
Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also considered an autoimmune disorder. There is no single cure for C3G, but several treatments may slow disease progression, protect ...
Dianthus Therapeutics focuses on developing DNTH103, a next-gen complement inhibitor for severe autoimmune diseases, currently in trials for CIDP, gMG, and MMN. Despite promising in vitro results, ...
Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will host a virtual R&D Day ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results